Cancer Screening — Early Detection in Healthy People

Screening in oncology refers to the systematic application of medical tests, examinations, or procedures across defined target populations who display no overt clinical signs of disease. The fundamental premise rests on identifying malignancies during their preclinical phase, before invasion or metastasis occurs, or detecting precursor lesions that can be excised before malignant transformation.

To be deemed effective and ethically justified, a screening modality must meet rigorous public health criteria: the disease must represent a substantial health burden with a recognisable latent stage, the screening test must demonstrate high sensitivity and specificity, and effective treatments must be readily accessible. Furthermore, the overall clinical benefits of early intervention must demonstrably outweigh potential screening-related harms, including false-positive results, procedural complications, overdiagnosis, and overtreatment of indolent abnormalities that might never have caused clinical harm.

Screening plays a pivotal role in oncological care because early detection fundamentally transforms clinical prognosis. Catching a tumour before it metastasises often allows for less aggressive, organ-sparing treatments, leading to fewer long-term side effects and substantially higher survival rates. Moreover, some screening procedures, such as colonoscopy or cervical cytology, can prevent cancer altogether by identifying and removing precancerous polyps or dysplastic cells. Understanding screening recommendations empowers individuals to make proactive, evidence-based choices about their health while engaging in informed discussions with clinicians regarding the benefits and limitations of specific tests.

Screening employs varied non-invasive and minimally invasive diagnostic modalities. These include radiological imaging (mammography, low-dose chest CT), endoscopic visual inspection (colonoscopy, sigmoidoscopy), and molecular or cytology tests (cervical liquid-based cytology, high-risk HPV DNA testing). Stool-based assays, such as faecal immunochemical testing (FIT) or multitarget stool DNA panels, screen for gastrointestinal bleeding or shed tumour markers. While screening tests indicate potential disease, definitive confirmation invariably requires formal tissue biopsy and histopathological verification.

Routine screening is well-established for several specific malignancies where population benefits are validated. These include breast cancer (via mammography), cervical cancer (via human papillomavirus testing and Pap cytology), colorectal cancer (via faecal occult blood tests and colonoscopy), and lung cancer (via low-dose computed tomography in high-risk individuals). Prostate cancer screening (using prostate-specific antigen tests) is often conducted through shared decision-making, while high-risk individuals may undergo targeted surveillance for melanoma, ovarian, or pancreatic cancers.

Screening alters management by catching disease at early, localised stages. Patients diagnosed through screening frequently require less intensive systemic chemotherapy, smaller surgical interventions (such as lumpectomy instead of mastectomy), or curative endoscopic resection for precancerous polyps without major surgery. In contrast, cancers diagnosed after symptom development are statistically more advanced, often requiring multimodal approaches combining extensive surgery, radiotherapy, and systemic therapies. Thus, screening shifts the therapeutic landscape toward less toxic, curative-intent treatments.